Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Official Title

A Phase 2 Multicentre Study of Autologous Tumour Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer


This is a prospective, open-label, multi-cohort, non-randomized, multicentre phase 2 study evaluating LN-145 in patients with metastatic NSCLC.

Trial Description

Primary Outcome:

  • Objective Response Rate
Secondary Outcome:
  • Objective Response Rate
  • Complete Response Rate
  • Duration of Response
  • Disease Control Rate
  • Progression-Free Survival
  • Overall Survival
  • Adverse Events
  • Core Biopsies
LN-145 is a ready-to-infuse, autologous TIL therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI and further optimized by Iovance for the treatment of patients with metastatic NSCLC. The cell transfer therapy used in this study involves patients receiving an NMA lymphocyte depleting preparative regimen, followed by infusion of autologous TIL, then finally followed by the administration of IL-2.

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society